Spontaneous bacterial peritonitis secondary prevention: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
m (Bot: Removing from Primary care)
 
(29 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Spontaneous bacterial peritonitis}}
{{Spontaneous bacterial peritonitis}}
{{CMG}}; {{AE}} {{ADI}}
{{CMG}}; {{AE}} {{SCh}}{{AY}}


==Overview==
==Overview==
Following a first episode of [[spontaneous bacterial peritonitis]], the recurrence rate at one year is ~70%, with a 1-year overall [[survival rate]] of 30-50% in patients who do not receive [[antibiotic]] [[prophylaxis]]. [[Cirrhosis|Cirrhotic patients]] with [[ascites]] and a prior history of [[SBP]], receiving [[antibiotic]] [[prophylaxis]] there is a reduction in the risk of recurrence from 68% to 20%. Accordingly, daily long-term [[antimicrobial prophylaxis]] are recommended for patients with a history of one or more episodes of [[SBP]].<ref name="pmid19561863">{{cite journal| author=Alaniz C, Regal RE| title=Spontaneous bacterial peritonitis: a review of treatment options. | journal=P T | year= 2009 | volume= 34 | issue= 4 | pages= 204-10 | pmid=19561863 | doi= | pmc=2697093 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19561863  }} </ref>


==Secondary Prevention==
==Secondary Prevention==
 
{| class="wikitable"
* All patients who have survived an episode of SBP should receive long-term prophylaxis with daily [[norfloxacin]] (or [[trimethoprim/sulfamethoxazole]]) because this is the most data-supported indication for long-term outpatient prophylaxis. <ref>http://guideline.gov/content.aspx?id=14887&search=ascitis</ref>
! colspan="6" |Secondary SBP prophylaxis
 
|-
* All cirrhotic patients might benefit from antibiotics if:
!Indications
** Ascitic fluid protein <1.0 g/dL<ref name="pmid3770358">{{cite journal |author=Runyon BA |title=Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis |journal=Gastroenterology |volume=91 |issue=6 |pages=1343-6 |year=1986 |pmid=3770358 |doi=}}</ref>. Patients with fluid protein <15 g/L and either Child-Pugh score of at least 9 or impaired renal function may also benefit.
!Preferred therapy
** Previous SBP<ref name="pmid9764990">{{cite journal |author=Grangé JD, Roulot D, Pelletier G, ''et al'' |title=Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial |journal=J. Hepatol. |volume=29 |issue=3 |pages=430-6 |year=1998 |pmid=9764990 |doi=}}</ref>
!Alternative therapy
!Duration of treatment
!Prognosis
!Complications
|-
|
* Previous history of [[SBP]]
|
* [[Norfloxacin]] 400 mg PO daily
|
* [[Sulfamethoxazole-Trimethoprim|Trimethoprim-sulfamethoxazole]] one DS tablet PO daily. 
* [[Ciprofloxacin]] 500 mg PO daily. 
* [[Levofloxacin]] 250 mg PO daily. 
* [[Rifaximin]]
|
* Indefinite, unless [[ascites]] resolves.
|
* Reduction in the recurrence rate of [[SBP]] from 68% to 20%.
|
* Prolonged use of [[antibiotic]] prophylaxis has led to the development of [[gram-negative]] bacterial resistance (to [[fluoroquinolones]] and [[Sulfamethoxazole-Trimethoprim|trimethoprim-sulfamethoxazole]]), as well as an increased likelihood of developing [[gram-positive]] infections.
|}
Several studies have shown that oral [[norfloxacin]] 400 mg '''daily''' prevents [[spontaneous bacterial peritonitis]] in patients with low-protein [[ascites]] and those with previous history of [[spontaneous bacterial peritonitis]] (SBP). [[Norfloxacin]] reduced SBP recurrence rates from 68% to 20%.
* Alternative regimens that have been studied include [[oral]] double-strength [[Sulfamethoxazole-Trimethoprim|trimethoprim-sulfamethoxazole]] 5 doses per week or oral [[ciprofloxacin]] 750 mg once a week, but intermittent dosing may lead to resistance.
* In addition, prolonged use of [[Antibiotic|antibiotic prophylaxis]] has led to the development of [[gram-negative]] bacterial [[resistance]] (to [[fluoroquinolones]] and [[Sulfamethoxazole-Trimethoprim|trimethoprim-sulfamethoxazole]]), as well as an increased likelihood of developing [[gram-positive]] infections. 
* Daily long-term dosing with [[norfloxacin]] has been proved to be superior to in-hospital administration of [[norfloxacin]].<ref name="NovellaSola1997">{{cite journal|last1=Novella|first1=M|last2=Sola|first2=R|last3=Soriano|first3=G|last4=Andreu|first4=M|last5=Gana|first5=J|last6=Ortiz|first6=J|last7=Coll|first7=S|last8=Sabat|first8=M|last9=Vila|first9=M C|last10=Guarner|first10=C|last11=Vilardell|first11=F|title=Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin|journal=Hepatology|volume=25|issue=3|year=1997|pages=532–536|issn=0270-9139|doi=10.1002/hep.510250306}}</ref>
* All patients who have survived an episode of SBP should receive long-term prophylaxis with daily [[norfloxacin]] (or [[trimethoprim/sulfamethoxazole]]) because this is the most data-supported indication for long-term outpatient prophylaxis to prevent future episodes ( 40-70% risk of recurrence in 1 year ). <ref>http://guideline.gov/content.aspx?id=14887&search=ascitis</ref><ref name="GinésRimola1990">{{cite journal|last1=Ginés|first1=Pere|last2=Rimola|first2=Antoni|last3=Planas|first3=Ramón|last4=Vargas|first4=Victor|last5=Marco|first5=Francesc|last6=Almela|first6=Manuel|last7=Forne|first7=Montserrat|last8=Miranda|first8=Maria Luisa|last9=Llach|first9=Josep|last10=Salmerón|first10=Joan Manuel|last11=Esteve|first11=Maria|last12=Marques|first12=Josep Maria|last13=de Anta|first13=Maria Teresa Jiménez|last14=Arroyo|first14=Vicente|last15=Rodés|first15=Joan|title=Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial|journal=Hepatology|volume=12|issue=4|year=1990|pages=716–724|issn=02709139|doi=10.1002/hep.1840120416}}</ref><ref name="pmid3770358">{{cite journal |author=Runyon BA |title=Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis |journal=Gastroenterology |volume=91 |issue=6 |pages=1343-6 |year=1986 |pmid=3770358 |doi=}}</ref><ref name="pmid9764990">{{cite journal |author=Grangé JD, Roulot D, Pelletier G, ''et al'' |title=Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial |journal=J. Hepatol. |volume=29 |issue=3 |pages=430-6 |year=1998 |pmid=9764990 |doi=}}</ref>
* [[Rifaximin]] was more effective than [[norfloxacin]] in the secondary prevention of [[SBP]] as [[encephalopathy]]-related mortality and side effects were fewer with [[rifaximin]] than [[norfloxacin]].<ref name="ElfertAbo Ali2016">{{cite journal|last1=Elfert|first1=Asem|last2=Abo Ali|first2=Lobna|last3=Soliman|first3=Samah|last4=Ibrahim|first4=Shimaa|last5=Abd-Elsalam|first5=Sherief|title=Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis|journal=European Journal of Gastroenterology & Hepatology|volume=28|issue=12|year=2016|pages=1450–1454|issn=0954-691X|doi=10.1097/MEG.0000000000000724}}</ref><ref name="DongAronsohn2016">{{cite journal|last1=Dong|first1=Tien|last2=Aronsohn|first2=Andrew|last3=Gautham Reddy|first3=K.|last4=Te|first4=Helen S.|title=Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis|journal=Digestive Diseases and Sciences|volume=61|issue=12|year=2016|pages=3621–3626|issn=0163-2116|doi=10.1007/s10620-016-4313-0}}</ref>


==References==
==References==
{{reflist|2}}
{{reflist|2}}


[[Category:Gastroenterology]]
[[Category:Emergency mdicine]]
[[Category:Emergency medicine]]
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 00:15, 30 July 2020

Peritonitis main page

Spontaneous bacterial peritonitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Spontaneous bacterial peritonitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Spontaneous bacterial peritonitis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Spontaneous bacterial peritonitis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Spontaneous bacterial peritonitis secondary prevention

CDC on Spontaneous bacterial peritonitis secondary prevention

Spontaneous bacterial peritonitis secondary prevention in the news

Blogs on Spontaneous bacterial peritonitis secondary prevention

Directions to Hospitals Treating Spontaneous bacterial peritonitis

Risk calculators and risk factors for Spontaneous bacterial peritonitis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shivani Chaparala M.B.B.S [2]Ahmed Younes M.B.B.CH [3]

Overview

Following a first episode of spontaneous bacterial peritonitis, the recurrence rate at one year is ~70%, with a 1-year overall survival rate of 30-50% in patients who do not receive antibiotic prophylaxis. Cirrhotic patients with ascites and a prior history of SBP, receiving antibiotic prophylaxis there is a reduction in the risk of recurrence from 68% to 20%. Accordingly, daily long-term antimicrobial prophylaxis are recommended for patients with a history of one or more episodes of SBP.[1]

Secondary Prevention

Secondary SBP prophylaxis
Indications Preferred therapy Alternative therapy Duration of treatment Prognosis Complications
  • Previous history of SBP
  • Indefinite, unless ascites resolves.
  • Reduction in the recurrence rate of SBP from 68% to 20%.

Several studies have shown that oral norfloxacin 400 mg daily prevents spontaneous bacterial peritonitis in patients with low-protein ascites and those with previous history of spontaneous bacterial peritonitis (SBP). Norfloxacin reduced SBP recurrence rates from 68% to 20%.

References

  1. Alaniz C, Regal RE (2009). "Spontaneous bacterial peritonitis: a review of treatment options". P T. 34 (4): 204–10. PMC 2697093. PMID 19561863.
  2. Novella, M; Sola, R; Soriano, G; Andreu, M; Gana, J; Ortiz, J; Coll, S; Sabat, M; Vila, M C; Guarner, C; Vilardell, F (1997). "Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin". Hepatology. 25 (3): 532–536. doi:10.1002/hep.510250306. ISSN 0270-9139.
  3. http://guideline.gov/content.aspx?id=14887&search=ascitis
  4. Ginés, Pere; Rimola, Antoni; Planas, Ramón; Vargas, Victor; Marco, Francesc; Almela, Manuel; Forne, Montserrat; Miranda, Maria Luisa; Llach, Josep; Salmerón, Joan Manuel; Esteve, Maria; Marques, Josep Maria; de Anta, Maria Teresa Jiménez; Arroyo, Vicente; Rodés, Joan (1990). "Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial". Hepatology. 12 (4): 716–724. doi:10.1002/hep.1840120416. ISSN 0270-9139.
  5. Runyon BA (1986). "Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis". Gastroenterology. 91 (6): 1343–6. PMID 3770358.
  6. Grangé JD, Roulot D, Pelletier G; et al. (1998). "Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial". J. Hepatol. 29 (3): 430–6. PMID 9764990.
  7. Elfert, Asem; Abo Ali, Lobna; Soliman, Samah; Ibrahim, Shimaa; Abd-Elsalam, Sherief (2016). "Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis". European Journal of Gastroenterology & Hepatology. 28 (12): 1450–1454. doi:10.1097/MEG.0000000000000724. ISSN 0954-691X.
  8. Dong, Tien; Aronsohn, Andrew; Gautham Reddy, K.; Te, Helen S. (2016). "Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis". Digestive Diseases and Sciences. 61 (12): 3621–3626. doi:10.1007/s10620-016-4313-0. ISSN 0163-2116.